NO20072631L - Kreftbehandlingsmetode - Google Patents

Kreftbehandlingsmetode

Info

Publication number
NO20072631L
NO20072631L NO20072631A NO20072631A NO20072631L NO 20072631 L NO20072631 L NO 20072631L NO 20072631 A NO20072631 A NO 20072631A NO 20072631 A NO20072631 A NO 20072631A NO 20072631 L NO20072631 L NO 20072631L
Authority
NO
Norway
Prior art keywords
treatment method
cancer treatment
administering
breast cancer
brain
Prior art date
Application number
NO20072631A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen Rubin
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072631(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of NO20072631L publication Critical patent/NO20072631L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20072631A 2004-12-17 2007-05-22 Kreftbehandlingsmetode NO20072631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63705204P 2004-12-17 2004-12-17
PCT/US2005/046350 WO2006066267A2 (en) 2004-12-17 2005-12-16 Cancer treatment method

Publications (1)

Publication Number Publication Date
NO20072631L true NO20072631L (no) 2007-07-02

Family

ID=36588668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072631A NO20072631L (no) 2004-12-17 2007-05-22 Kreftbehandlingsmetode

Country Status (14)

Country Link
US (2) US20080306097A1 (ja)
EP (1) EP1824492B1 (ja)
JP (1) JP5291345B2 (ja)
KR (1) KR20070107004A (ja)
CN (1) CN101083995A (ja)
AU (1) AU2005316238B2 (ja)
ES (1) ES2426007T3 (ja)
IL (1) IL183059A0 (ja)
MX (1) MX2007006043A (ja)
NO (1) NO20072631L (ja)
NZ (1) NZ555462A (ja)
RU (1) RU2007119432A (ja)
WO (1) WO2006066267A2 (ja)
ZA (1) ZA200705059B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1906185A1 (en) * 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
CN102421427B (zh) * 2009-03-11 2013-11-06 阿迪生物科学公司 用于治疗特定癌症的包含rdea119/bay869766的药物组合
CN102146075B (zh) * 2010-02-06 2014-04-02 浙江九洲药业股份有限公司 一种喹唑啉化合物的制备方法
US8710221B2 (en) 2010-03-23 2014-04-29 Scinopharm Taiwan, Ltd. Process and intermediates for preparing lapatinib
CA2793742C (en) * 2010-03-23 2015-06-23 Scinopharm Taiwan Ltd. Process and intermediates for preparing lapatinib
CN102344445B (zh) * 2010-07-23 2015-11-25 岑均达 光学纯喹唑啉类化合物
CN102344444B (zh) * 2010-07-23 2015-07-01 岑均达 光学纯喹唑啉类化合物
CN102321076B (zh) * 2011-07-07 2013-08-21 中国科学技术大学 拉帕替尼中间体及其类似物的制备方法
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN106632276B (zh) * 2015-10-28 2021-06-15 上海天慈生物谷生物工程有限公司 一种治疗乳腺癌药物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
WO2005120512A2 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Cancer treatment method

Also Published As

Publication number Publication date
MX2007006043A (es) 2007-06-13
JP2008524258A (ja) 2008-07-10
ZA200705059B (en) 2009-09-30
RU2007119432A (ru) 2009-01-27
US20080306097A1 (en) 2008-12-11
CN101083995A (zh) 2007-12-05
ES2426007T3 (es) 2013-10-18
EP1824492B1 (en) 2013-07-10
EP1824492A4 (en) 2009-10-28
AU2005316238A1 (en) 2006-06-22
JP5291345B2 (ja) 2013-09-18
NZ555462A (en) 2009-03-31
WO2006066267A2 (en) 2006-06-22
KR20070107004A (ko) 2007-11-06
WO2006066267A3 (en) 2006-12-14
US20150283139A1 (en) 2015-10-08
IL183059A0 (en) 2007-10-31
EP1824492A2 (en) 2007-08-29
AU2005316238B2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
NO20072631L (no) Kreftbehandlingsmetode
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
EA200801041A1 (ru) Ингибиторы мек и способы их применения
IN2014KN02886A (ja)
IL199403A0 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
NO20066079L (no) Behandlingsmetode for cancer
DE602007011628D1 (de) Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
NO20074366L (no) Fremgangsmate for a behandle gefitmibresistent kreft
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
MX2023001468A (es) Tratamiento de cancer de prostata.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
NO20066077L (no) Behandlingsmetode for cancer
SA521431048B1 (ar) مركبات بيروليدين
EA202192757A1 (ru) Способ лечения опухолей
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
ZA200609220B (en) Method of treating dry eye disorders and uveitis
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
EA201991570A1 (ru) Амидные соединения и их применение
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
EA202193211A1 (ru) Лечение синуклеопатий
BR112022001627A2 (pt) Composições farmacêuticas, minicomprimido, embalagem do tipo stickpack, kit, processo para produzir a composição farmacêutica, métodos para o tratamento de doenças e para tratar tipos específicos de câncer, método de tratamento de câncer em um paciente em necessidade do mesmo e invenção
DE60236894D1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application